Medicine software company
Be an early applicant
Medicine software company
201-500 employees
Be an early applicant
201-500 employees
To transform patient care by expanding access to data-driven medicine globally.
Jump to section
To transform patient care by expanding access to data-driven medicine globally.
Though health and genetic data are increasingly available in large quantities to healthcare providers, it can be very difficult to gain insights from it. Data processing is a significant bottleneck, and important information which could be vital to a patient's health can easily be overlooked or misinterpreted. SOPHiA GENETICS has developed a SaaS platform which seeks to change this, by processing raw data received from partner institutions and then returning a standardised report which can be actioned by the end user. The platform then learns from this process, becoming more capable the more data it receives.
The global healthcare AI market is thriving, with numerous large competitors in the sector such as Welltok, iCarbonX and IBM (Watson Health). However, SOPHiA's USP is its support of democratizing health data, which means that it has continually worked closely with a variety of healthcare providers each using different instruments, and providing non-standardized data. While this was initially a hurdle, once overcome it has become a strength, allowing the platform to engage with the equipment a healthcare provider has rather than requiring a particular inventory.
SOPHiA went public in 2021 and since then has pursued collaborations with institutions and companies that focus on cancer screening and diagnostics. Most recently the company launched advanced MRD tracking capabilities, further innovating in the oncology space. With these cutting-edge tools. SOPHiA strengthens its leadership in data-driven medicine, paving the way for more personalized healthcare.
Freddie
Company Specialist at Welcome to the Jungle
Oct 2020
$110m
SERIES F
Jan 2019
$69.8m
SERIES E
This company has top investors
Jurgi Camblong
(Co-Founder & CEO)Previously the CEO at Gene Predictis. Prior to that, they were a Post-doctoral Associate Researcher at Oxford University.
Marketing
Finance, Legal & Compliance
Other Engineering